
JPMorgan Research Analysis: Moderna's INT Trial Reaches Its Endpoint, But Already Priced Into the Market
By Rita
On August 19, JPMorgan published a research report stating that Moderna's individualized neoantigen therapy (INT), developed in collaboration with Merck, met its primary endpoint in adjuvant melanoma, with significantly improved recurrence-free survival. The key secondary endpoint of distant metastasis-free survival was also achieved. However, this result was in line with expectations, and the market had already priced it into the stock prior to the announcement.
Following the announcement, Moderna's stock rose in premarket trading. JPMorgan maintained its Underweight rating and $40 price target, implying a 36% downside from the current $63. The core logic is that the success in adjuvant melanoma is already priced in, and Moderna's next value driver depends on whether INT can replicate this success across broader indications.
Melanoma Results Align with 85% Success Expectation
JPMorgan previously assigned an 85% probability of success to INT's Phase III clinical trial for adjuvant melanoma. This assessment was based on the robust efficacy signals demonstrated by INT in Phase IIb data, as well as the biological rationale for this mechanism in oncology immunotherapy.
Recurrence-free survival served as the primary endpoint, while distant metastasis-free survival was the key secondary endpoint. Citing a melanoma expert, JPMorgan noted that distant metastasis-free survival is an "extremely meaningful endpoint" and "where the real value lies." The onset of distant metastasis often signals a significant deterioration in prognosis. Delaying or preventing it holds substantial clinical significance for improving patients' quality of life and overall survival.
The research report concludes that this result itself is not an incremental catalyst for the stock price. Prior to the announcement, Moderna's market capitalization was nearing $25 billion, and JPMorgan believes this already includes expectations for INT's approval in adjuvant melanoma. After risk adjustment, this indication contributes only about 3% to JPMorgan's valuation.
Cross-Indication Data for INT Is the Key Variable
Adjuvant treatment for melanoma represents a relatively small indication within the oncology immunotherapy landscape. The combination of INT with Merck's Keytruda demonstrates clear clinical value, but the addressable market remains limited. To sustain a $25 billion market cap, Moderna needs INT to prove equally effective in other indications.
JPMorgan's valuation model already factors in approximately $15 per share in risk-adjusted value for INT's potential across non-melanoma indications. The report remains focused on INT's data releases and follow-up trials in non-melanoma indications, as these will ultimately drive valuation assessments.
Adjuvant melanoma is the most advanced indication in INT's pipeline, but far from the end goal. Clinical development across other cancer types will determine the ceiling for INT as a platform technology. From a biological mechanism perspective, the rationale for personalized neoantigen therapy is not limited to melanoma; it holds theoretical feasibility in highly immunogenic tumor types such as lung cancer, head and neck cancer, and renal cell carcinoma. However, theoretical feasibility does not equate to clinical validation; subsequent data will be the decisive factor.
Valuation Logic Behind the $40 Price Target
JPMorgan's $40 price target is based on a DCF valuation model, utilizing a 10.5% weighted average cost of capital and a 0% terminal growth rate. This valuation covers Moderna's existing commercial products and its risk-adjusted pipeline value.
Upside risks include better-than-expected data for INT in non-melanoma indications, accelerated regulatory approval timelines, and improved demand for the vaccine business amid policy shifts. Downside risks reflect typical pharmaceutical challenges facing Moderna in mRNA platform competition: clinical failures, regulatory delays, and slower-than-anticipated commercial ramp-up.
The premarket gain primarily reflects short covering and short-term trading sentiment rather than structural changes in fundamentals. Performance of INT across other indications will dictate the valuation ceiling. If future data demonstrates clinical activity for this platform technology across additional tumor types, Moderna's valuation will see a significant upward revision. Conversely, if data falls short of expectations, the portion of cross-indication value already priced into the current stock may contract.
JPMorgan maintains its bearish stance. The clinical value of INT in melanoma is clear, but it has already been fully priced in. What Moderna must prove is INT's comparable efficacy across a broader range of cancers.

Disclaimer
This article is compiled and interpreted by Chaoxiang Research based on a third-party broker research report (JPMorgan, August 19, 2026), combined with public market information. The ratings, price targets, earnings forecasts, and related judgments cited herein represent the views of the respective broker's analysts, solely reflecting their institutional standpoint, not those of Chaoxiang Research, and do not constitute any investment advice.
The market involves risks, and decisions should be made independently. This article should not serve as the basis for buying or selling any securities.














